Full-Time

Marketing Director

Haematology

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

£104.9k - £131.1k/yr

Remote in UK

Hybrid

Category
Growth & Marketing (1)
Required Skills
Forecasting
Marketing
Requirements
  • University undergraduate degree in science or business.
  • A minimum of 10 years of pharmaceutical industry marketing or related experience.
  • UK marketplace launch experience required.
  • Willingness to travel (approximately 25%).
Responsibilities
  • Develop the overall Haematology strategy and tactical plans to support the UK and Ireland commercialisation of BeOne’s portfolio.
  • Oversee all marketing strategies and plans in collaboration with BeOne global teams and commercialisation partners to realise maximal value in the UK and Ireland.
  • Prepare the commercial market for the approval of BeOne’s future products in Haematology.
  • Partner with Sales, Market Access and Medical Affairs to ensure alignment of BeOne’s UK and Ireland commercialisation strategy.
  • Collation and development of market insights that inform commercial strategies, tactics and product forecasts.
  • Partner with Medical Affairs on the execution and development of an integrated scientific and thought leadership strategy.
  • Build strong partnerships with external partners and influence commercial strategy for partnered assets.
  • Localise and implement the strategy through various programs/channels (events, webinars, congresses, inbound, content syndication, direct mail, digital advertising etc.) including digital.
  • Guide development of tactics to proactively address identified challenges/hurdles.
  • Establish strong relationships and future-oriented collaborations with key opinion leaders (KOLs) and key accounts.
  • Collaborate with key customers and patient advocates to develop relevant content in line with strategic objectives.
  • Guide development of promotional materials and activities.
  • Steer impactful congress presence, communications and intelligence.
  • Gain insights from market (HCPs, KOLs, patient groups) and identify therapeutic hurdles, opportunities and trends.
  • Gather and interpret competitor intelligence.
  • Partner with the field force to understand their resource gaps and opportunities through building strong relationships.
  • Demonstrate marketing thought leadership and represents BeOne at key meetings and conferences, etc., when appropriate.
  • Oversee overall Haematology marketing budget ensuring appropriate spend and ROI on all marketing activities.
  • Provide exceptional leadership, fostering an environment to drive high performance, engagement, accountability, empowerment, and behaviours fully consistent with BeOne’s values and culture.
  • Fosters a leadership culture which attracts, develops and retains candidates, create effective internal communication and foster teamwork.
  • Drive business decisions whereby patient care is at the center of the business conduct.
  • Ensure team compliance across all areas to maintain the highest standards of patients focused ethical conduct in line with our values.
  • Consistently ensure operating in accordance with BeOne’s Standards of conduct and all applicable local laws and regulations.
Desired Qualifications
  • Specific knowledge and experience in the hematology market / knowledge in the field of lymphomas is highly desirable.
  • Demonstrated success in a small but fast growing, entrepreneurial commercial environment.
  • Highly skilled in influencing cross-functional teams, including interfacing with key internal and external stakeholders and with scientific and commercial teams.
  • Excellent interpersonal, oral and written communication skills, including ability to synthesize data and deliver a clear overview of commercial strategy, opportunity and risks for the Executive Team.
  • Scientific + solution-oriented mindset and capability to move and execute in a rapidly changing, ambiguous environment.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • BRUKINSA sales reached $3.9B in 2025, growing 49% year-over-year.
  • TEVIMBRA plus ZIIHERA shows extended survival versus trastuzumab in gastric cancer.
  • Three solid tumor programs advancing to late-stage trials with 60+ abstracts.

What critics are saying

  • BRUKINSA represents 73% of revenue; market share loss to competitors accelerates decline.
  • BEQALZI conditional approval requires CELESTIAL-RRMCL Phase 3 trial success by 2027.
  • Generic ibrutinib competition by 2027-2028 forces BRUKINSA price cuts or market share loss.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL.
  • BEQALZI is first BCL2 inhibitor approved for relapsed/refractory mantle cell lymphoma.
  • Global GMP manufacturing network enables cost-efficient drug development across 45+ countries.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at BeOne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...